# CNS Sector

Canonical URL: https://biopharmsignal.com/sector/cns

CNS refers to central nervous system diseases such as depression, schizophrenia, epilepsy, Alzheimer's disease, Parkinson's disease, and other neurological or psychiatric conditions. Companies on this page are grouped by their exposure to brain and nervous system therapeutics.

Companies currently grouped under CNS: 52

## Recent Sector News

- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c) — Source: ACADIA Pharmaceuticals Inc.
- 2026-07-16 12:00 EST — ALNY — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-15 20:05 EST — ACAD — [Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-to-announce-second-quarter-2026-financial-results-on-augu-562a4f56) — Source: ACADIA Pharmaceuticals Inc.
- 2026-07-15 13:05 EST — TNXP — [Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models](https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-publication-in-the-peer-reviewed-journal-of-viro-14c8c277) — Source: Tonix Pharmaceuticals
- 2026-07-15 12:00 EST — ALNY — [Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurologi](https://biopharmsignal.com/news/ALNY/alnylam-highlights-progress-with-neuroscience-programs-at-aaic-2026-showcasing-p-508fc61d) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-15 11:00 EST — AXGN — [Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026](https://biopharmsignal.com/news/AXGN/axogen-inc-to-report-second-quarter-2026-financial-results-on-july-29-2026-56aa71ab) — Source: AxoGen
- 2026-07-14 12:00 EST — PMN — [ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026](https://biopharmsignal.com/news/PMN/promis-neurosciences-reports-first-human-evidence-of-amyloid-beta-oligomer-targe-5218a89a) — Source: ProMIS Neurosciences
- 2026-07-13 11:00 EST — TNXP — [Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®](https://biopharmsignal.com/news/TNXP/tonix-pharmaceuticals-announces-major-managed-medicare-payer-agreement-for-tonmy-bb25eccc) — Source: Tonix Pharmaceuticals
- 2026-07-09 18:25 EST — ALNY — [Alnylam to Webcast Presentations at Upcoming Investor Conferences](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-presentations-at-upcoming-investor-conferences-50fb6676) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:25 EST — ALNY — [New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutris](https://biopharmsignal.com/news/ALNY/new-data-analyses-presented-at-heart-failure-2026-demonstrate-robust-and-consist-d10768e9) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:24 EST — ALNY — [Alnylam Issues 2025 Corporate Responsibility Report](https://biopharmsignal.com/news/ALNY/alnylam-issues-2025-corporate-responsibility-report-62023cfe) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:24 EST — ALNY — [Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics](https://biopharmsignal.com/news/ALNY/alnylam-and-inceptive-form-strategic-ai-collaboration-to-accelerate-the-discover-3d8b2b06) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 18:24 EST — ALNY — [Alnylam to Host Tenth “RNAi Roundtable” Webcast Series](https://biopharmsignal.com/news/ALNY/alnylam-to-host-tenth-rnai-roundtable-webcast-series-3988e623) — Source: Alnylam Pharmaceuticals, Inc.
- 2026-07-09 00:00 EST — TEVA — [Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (](https://biopharmsignal.com/news/TEVA/teva-and-polpharma-biologics-announce-global-licensing-agreement-for-a-biosimila-958342ff) — Source: Teva Pharmaceutical Industries
- 2026-07-08 11:02 EST — KTTA — [Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-participation-in-b-riley-securities-mind-muscle--c2ef8757) — Source: Pasithea Therapeutics
- 2026-07-07 00:00 EST — TEVA — [Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Viti](https://biopharmsignal.com/news/TEVA/teva-to-advance-its-anti-il-15-antibody-designed-for-quarterly-dosing-into-phase-505de9a8) — Source: Teva Pharmaceutical Industries
- 2026-07-06 13:04 EST — ACAD — [Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-appoints-carl-segerstrom-as-chief-people-officer-1598bf7e) — Source: ACADIA Pharmaceuticals Inc.
- 2026-07-06 12:45 EST — NRSN — [NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"](https://biopharmsignal.com/news/NRSN/neurosense-to-participate-in-roth-hosted-kol-webinar-on-the-future-of-als-treatm-467c5922) — Source: NeuroSense Therapeutics
- 2026-07-06 12:30 EST — STIM — [Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026](https://biopharmsignal.com/news/STIM/neuronetics-to-participate-in-a-panel-discussion-at-b-riley-securities-mind-musc-e3db286d) — Source: Neuronetics
- 2026-07-02 20:01 EST — XENE — [Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XENE/xenon-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-f5979058) — Source: Xenon

## Companies

- [ABBV](https://biopharmsignal.com/company/ABBV) — AbbVie Inc
- [ACIU](https://biopharmsignal.com/company/ACIU) — AC Immune
- [ACAD](https://biopharmsignal.com/company/ACAD) — ACADIA Pharmaceuticals Inc.
- [ALNY](https://biopharmsignal.com/company/ALNY) — Alnylam Pharmaceuticals, Inc.
- [ATHE](https://biopharmsignal.com/company/ATHE) — Alterity Therapeutics
- [AMPH](https://biopharmsignal.com/company/AMPH) — Amphastar Pharmaceuticals, Inc.
- [AMLX](https://biopharmsignal.com/company/AMLX) — Amylyx
- [ARGX](https://biopharmsignal.com/company/ARGX) — Argenx
- [ASRT](https://biopharmsignal.com/company/ASRT) — Assertio
- [ATHA](https://biopharmsignal.com/company/ATHA) — Athira Pharma
- [AXGN](https://biopharmsignal.com/company/AXGN) — AxoGen
- [AXNX](https://biopharmsignal.com/company/AXNX) — Axonics
- [AXSM](https://biopharmsignal.com/company/AXSM) — Axsome
- [BIIB](https://biopharmsignal.com/company/BIIB) — Biogen
- [BNOX](https://biopharmsignal.com/company/BNOX) — Bionomics
- [BIVI](https://biopharmsignal.com/company/BIVI) — BioVie Inc.
- [BTAI](https://biopharmsignal.com/company/BTAI) — BioXcel
- [SAVA](https://biopharmsignal.com/company/SAVA) — Cassava Sciences
- [CPRX](https://biopharmsignal.com/company/CPRX) — Catalyst Pharmaceutical
- [CGTX](https://biopharmsignal.com/company/CGTX) — Cognition Therapeutics
- [DNLI](https://biopharmsignal.com/company/DNLI) — Denali Therapeutics
- [ECOR](https://biopharmsignal.com/company/ECOR) — electroCore
- [ELYM](https://biopharmsignal.com/company/ELYM) — Eliem Therapeutics
- [HSDT](https://biopharmsignal.com/company/HSDT) — Helius Medical Technologies
- [ITCI](https://biopharmsignal.com/company/ITCI) — Intra-Cellular Therapies
- [LEGN](https://biopharmsignal.com/company/LEGN) — Legend Biotech Corporation
- [LBPH](https://biopharmsignal.com/company/LBPH) — Longboard Pharmaceuticals
- [MNMD](https://biopharmsignal.com/company/MNMD) — MindMed
- [NERV](https://biopharmsignal.com/company/NERV) — Minerva Neuroscience
- [NGEN](https://biopharmsignal.com/company/NGEN) — NervGen Pharma
- [NMRA](https://biopharmsignal.com/company/NMRA) — Neumora Therapeutics
- [NBIX](https://biopharmsignal.com/company/NBIX) — Neurocrine Biosciences
- [NGNE](https://biopharmsignal.com/company/NGNE) — Neurogene
- [NURO](https://biopharmsignal.com/company/NURO) — Neurometrix
- [STIM](https://biopharmsignal.com/company/STIM) — Neuronetics
- [NRSN](https://biopharmsignal.com/company/NRSN) — NeuroSense Therapeutics
- [NKGN](https://biopharmsignal.com/company/NKGN) — NKGen Biotech, Inc.
- [NLSP](https://biopharmsignal.com/company/NLSP) — NLS Pharmaceutics Ltd.
- [NRXP](https://biopharmsignal.com/company/NRXP) — NRX Pharmaceuticals, Inc.
- [ORPH](https://biopharmsignal.com/company/ORPH) — Orphazyme
- [KTTA](https://biopharmsignal.com/company/KTTA) — Pasithea Therapeutics
- [PXMD](https://biopharmsignal.com/company/PXMD) — PaxMedica
- [PMN](https://biopharmsignal.com/company/PMN) — ProMIS Neurosciences
- [SRPT](https://biopharmsignal.com/company/SRPT) — Sarepta Therapeutics
- [SUPN](https://biopharmsignal.com/company/SUPN) — Supernus
- [SNPX](https://biopharmsignal.com/company/SNPX) — Synaptogenix
- [TAK](https://biopharmsignal.com/company/TAK) — Takeda
- [TEVA](https://biopharmsignal.com/company/TEVA) — Teva Pharmaceutical Industries
- [TNXP](https://biopharmsignal.com/company/TNXP) — Tonix Pharmaceuticals
- [VIGL](https://biopharmsignal.com/company/VIGL) — Vigil Neuroscience
- [XENE](https://biopharmsignal.com/company/XENE) — Xenon
- [ZLAB](https://biopharmsignal.com/company/ZLAB) — Zai Lab Limited